Identification of Anti-Mycobacterial Biofilm Agents Based on the 2-Aminoimidazole Scaffold

ChemMedChem. 2019 May 6;14(9):927-937. doi: 10.1002/cmdc.201900033. Epub 2019 Mar 21.

Abstract

Tuberculosis (TB) remains a significant global health problem for which new therapeutic options are sorely needed. The ability of the causative agent, Mycobacterium tuberculosis, to reside within host macrophages and form biofilm-like communities contributes to the persistent and drug-tolerant nature of the disease. Compounds that can prevent or reverse the biofilm-like phenotype have the potential to serve alongside TB antibiotics to overcome this tolerance, and decrease treatment duration. Using Mycobacterium smegmatis as a surrogate organism, we report the identification of two new 2-aminoimidazole compounds that inhibit and disperse mycobacterial biofilms, work synergistically with isoniazid and rifampicin to eradicate preformed M. smegmatis biofilms in vitro, are nontoxic toward Galleria mellonella, and exhibit stability in mouse plasma.

Keywords: 2-aminoimidazoles; biofilms; mycobacteria; synergy; tuberculosis.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antitubercular Agents / chemistry
  • Antitubercular Agents / pharmacology*
  • Biofilms / drug effects*
  • Imidazoles / chemistry*
  • Male
  • Mice
  • Microsomes / drug effects
  • Microsomes / metabolism
  • Mycobacterium tuberculosis / drug effects*

Substances

  • Antitubercular Agents
  • Imidazoles
  • 2-aminoimidazole